Rafal Kaminski from Angelini Pharma tells Pharmafocus about the global challenge of epilepsy as well as how his company is striving to bridge the gaps in epilepsy treatment

Ahead of clinical trials day, Soraya Bekkali, from Alexion, AstraZeneca Rare Disease, highlights the urgent need to elevate patients’ voices to accelerate rare disease innovation

Rob Conley from Beckley Psytech tells Pharmafocus about the use of psychedelic medicine for the treatment of psychiatric and neurological conditions, and how this field could develop in the future

Kabir Nath from Compass Pathways explores the need for new treatments in the mental health space, as well as assessing whether psychoactives could be the way forward

Sebastien Noel from Veeva Systems considers the potential benefits and drawbacks of messaging services for HCPs as well as explaining Veeva’s own platform, which combats these issues

Alex Devereson and Delphine Zurkiya from McKinsey consider the value of generative AI in the pharma industry

Frances Ramsay from InnoScot Health discusses the way forward in closing the gender health gap

Dr Charlotte Owens from Organon explores the impact of innovations in contraception and how this can reduce unintended pregnancy rates

Professor Tobias Arkenau from Ellipses Pharma explores the need and potential for next generation treatments as well as the global need to keep improving the clinical trial structure and landscape

Dr Gen Li, president at Phesi, considers patient enrolment and retention in clinical trials, with a focus on oncology trials and the challenges facing them

Santosh Sahu at Charac considers the NHS’ Pharmacy First scheme, it benefits and the barriers to its implementation

Pharmafocus speaks to Gilead Sciences about the current treatments available for blood cancers and how they are likely to develop in the future